Joe M. McCord

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Joe Milton McCord
Residence Denver, Colorado
Citizenship United States
Fields Biochemistry
Institutions University of Colorado
Alma mater Rhodes College, Duke University
Doctoral advisor Irwin Fridovich
Known for Discovery of superoxide dismutase

Joe Milton McCord (born March 3, 1945) is an American biochemist. While serving as a graduate student, he and his supervisor Irwin Fridovich were the first to describe the enzymatic activity of superoxide dismutase.[1][2] McCord joined the board of directors of the LifeVantage Corporation (makers of the dietary supplement Protandim) in 2006, serving as the company's chief science officer from 2011 to 2012, and retired from the company in June 2013.[3]

Academic Background[edit]

McCord received a B.S. degree in chemistry from Rhodes College (graduated 1966) and a Ph.D. in biochemistry from Duke University (graduated 1970), where he also conducted postdoctoral research.[citation needed]

McCord has held biochemistry faculty positions at Duke University Medical Center, University of South Alabama, and the University of Colorado Denver.[citation needed]

McCord is a past recipient of the Elliott Cresson Medal, the Discovery Award from the Society for Free Radical Biology and Medicine (SFRBM),[4] and a Lifetime Achievement Award from the Oxygen Society. He holds an Honorary Doctorate from the University of Buenos Aires and has served as Honorary President of the International Society of Antioxidants in Nutrition and Health (ISANH) and as Chairman of the Third International Conference on Superoxide Dismutases at the Institut Pasteur.[citation needed]

LifeVantage/Protandim[edit]

McCord has served on the board of directors (Director of Science) of the LifeVantage Corporation since 2006[5] and is listed by the SEC as an insider shareholder.[6] LifeVantage is a Utah-based multilevel marketing company that distributes an antioxidant dietary supplement known as Protandim. McCord has co-authored 7 studies on the product[7][8][9][10][11][12][13] and participates in distributor training.[6] McCord served as Chief Scientific Officer for LifeVantage from June 2011 until September 2012, and then became a member of the company's science advisory board. LifeVantage announced McCord’s retirement in June 2013.[3][14] Under the terms of the separation agreement, McCord was to receive a payment of $1.7 million from the company.[14]

Publications[edit]

McCord has published articles in various scientific journals and books.[15]

References[edit]

  1. ^ McCord JM, Fridovich I (November 1969). "Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein)". J. Biol. Chem. 244 (22): 6049–55. PMID 5389100. 
  2. ^ Keele BB, McCord JM, Fridovich I (November 1970). "Superoxide dismutase from escherichia coli B. A new manganese-containing enzyme". J. Biol. Chem. 245 (22): 6176–81. PMID 4921969. 
  3. ^ a b http://globenewswire.com/news-release/2013/06/25/556132/10037495/en/Dr-Joe-McCord-LifeVantage-Corporation-s-First-Chief-Science-Officer-Retires-From-Company.html[full citation needed]
  4. ^ "SFRBM - Society for Free Radical Biology and Medicine". 
  5. ^ http://www.allbusiness.com/company-activities-management/board-management/5376294-1.html[full citation needed]
  6. ^ a b http://secwatch.com/mccord-joe-m[full citation needed]
  7. ^ Nelson SK, Bose SK, Grunwald GK, Myhill P, McCord JM (January 2006). "The induction of human superoxide dismutase and catalase in vivo: a fundamentally new approach to antioxidant therapy". Free Radic. Biol. Med. 40 (2): 341–7. doi:10.1016/j.freeradbiomed.2005.08.043. PMID 16413416. 
  8. ^ Velmurugan K, Alam J, McCord JM, Pugazhenthi S (February 2009). "Synergistic induction of heme oxygenase-1 by the components of the antioxidant supplement Protandim". Free Radic. Biol. Med. 46 (3): 430–40. doi:10.1016/j.freeradbiomed.2008.10.050. PMID 19056485. 
  9. ^ Liu J, Gu X, Robbins D, et al. (2009). "Protandim, a fundamentally new antioxidant approach in chemoprevention using mouse two-stage skin carcinogenesis as a model". PLoS ONE 4 (4): e5284. doi:10.1371/journal.pone.0005284. PMC 2668769. PMID 19384424. 
  10. ^ Robbins D, Gu X, Shi R, et al. (2010). "The chemopreventive effects of Protandim: modulation of p53 mitochondrial translocation and apoptosis during skin carcinogenesis". PLoS ONE 5 (7): e11902. doi:10.1371/journal.pone.0011902. PMC 2912769. PMID 20689586. 
  11. ^ Bogaard HJ, Natarajan R, Henderson SC, et al. (November 2009). "Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure". Circulation 120 (20): 1951–60. doi:10.1161/CIRCULATIONAHA.109.883843. PMID 19884466. 
  12. ^ Qureshi MM, McClure WC, Arevalo NL, et al. (June 2010). "The Dietary Supplement Protandim Decreases Plasma Osteopontin and Improves Markers of Oxidative Stress in Muscular Dystrophy Mdx Mice". J Diet Suppl 7 (2): 159–178. doi:10.3109/19390211.2010.482041. PMC 2926985. PMID 20740052. 
  13. ^ Joddar B, Reen RK, Firstenberg MS, et al. (March 2011). "Protandim attenuates intimal hyperplasia in human saphenous veins cultured ex vivo via a catalase-dependent pathway". Free Radic. Biol. Med. 50 (6): 700–9. doi:10.1016/j.freeradbiomed.2010.12.008. PMID 21167278. 
  14. ^ a b "Form 8-K for LifeVantage Corp". Yahoo.com. June 25, 2013. Retrieved 11/10/2013. 
  15. ^ Search Results for author McCord JM on PubMed.

External links[edit]